Cargando…
TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study
Autores principales: | Lawitz, Eric, Loomba, Rohit, Denham, Douglas, Chung, Diana, Quirk, Erin, Lee, Lois, Marmon, Tonya, Kowdley, Kris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Association for the Study of the Liver. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252355/ http://dx.doi.org/10.1016/S0168-8278(22)01748-2 |
Ejemplares similares
-
Exposure to the SARS-CoV-2 spike protein in an in vitro model of steatosis enhances hepatocyte oxidative stress: implications for COVID-19 and accelerated disease progression
por: Jacobs, Angus, et al.
Publicado: (2022) -
P203 Earlier identification of human immunodeficiency virus and hepatitis C virus in high-risk emergency departments
por: Fenton, J., et al.
Publicado: (2009) -
Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease
por: Schwimmer, J B, et al.
Publicado: (2013) -
Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease
por: Shen, Feng, et al.
Publicado: (2015) -
Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) is associated with worse outcomes in patients hospitalised for COVID-19: a real-world analysis of a large population from the premier healthcare database
por: Tacke, Frank, et al.
Publicado: (2022)